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Abstract: We designed the present case-control study in order to examine the validity of apolipoprotein (apo) A-I, B, 
apoB/apoA-I ratio and Lp(a) as alternative markers of cardiovascular morbidity in end-stage renal disease (ESRD) patients 
undergoing chronic hemodialysis (HD). Twenty-ﬁ  ve HD patients (18 males, mean age 63, range 52–69 years) comprised 
the group with prevalent cardiovascular disease (CVD) and 50 HD patients (35 males, mean age 62, range 40–77 years) 
with non evident cardiovascular disease history constituted the second study group. Patients with CVD had signiﬁ  cantly 
higher concentrations of serum apoB, apoB/apoA-I ratio and Lp(a), and lower levels of apoA-I compared to patients with-
out incident CVD. All three parameters studied were correlated with cardiovascular morbidity, i.e. apoA-I negatively and 
apoB and apoB/apoA-I ratio positively (r = –0.6, P < 0.05; r = 0.659, P < 0.01; and r = 0.614, P < 0.01, respectively). Fur-
thermore, logCRP exhibited as well a signiﬁ  cant positive correlation with cardiovascular morbidity (r = 0.704, P < 0.001), 
not this being the case for Lp(a) which was not found to exhibit such a correlation (r = 0.05, P = NS). Among them, apoB 
and apoB/apoA-I ratio exhibited the characteristics most coherent to CVD. The age- and sex-adjusted OR for the presence 
of CVD was 2.3 and 2.0, respectively, which remained independent of any confounding effect of inﬂ  ammation. In conclu-
sion, serum apoB levels and apoB/apoA-I ratio exhibit characteristics of credible independent markers of in HD patients.
Keywords: cardiovascular disease, lipids, apolipoproteins, lipoprotein (a), hemodialysis, validation.
Introduction
Serum lipid proﬁ  le has long been considered to be amongst the principal cardiovascular disease risk 
factors in the general population as well as end-stage renal disease (ESRD) patients on chronic hemo-
dialysis (HD). Large epidemiological and clinical studies have consistently shown that elevated serum 
low-density lipoprotein (LDL) cholesterol levels are associated with increased risk of cardiovascular 
disease (CVD) (Grundy, 2002; De Backer et al. 2003; Grundy et al. 2004). The Adult Treatment Panel 
III (ATP) report of the U.S. National Cholesterol Education Program (NCEP) accordingly identiﬁ  ed 
elevated LDL cholesterol as the primary target of lipid-lowering therapy for reducing CVD risk (Adult 
Treatment Panel III 2001). Although the contribution of LDL to the development of atherosclerosis is 
well established, its superiority as marker of cardiovascular morbidity and mortality over other circu-
lating constituents of lipid proﬁ  le is debatable. This holds true both for the general population as well 
as HD patients, the later even more since there is hard evidence that some lipid constituents have a 
reverse prognostic signiﬁ  cance compared to the former population (Coresh et al. 1998; Lowrie and 
Lew, 1990; Iseki et al. 2002). Amongst other predictors of cardiovascular outcome that have been studied 
over the last years, lipoprotein(a) (Lp(a)) (Tsimikas et al. 2005; Danesh et al. 2000; Cressman et al. 
1992) and apolipoproteins (apo) A-I and B (Lamarche et al. 1996; St-Pierre et al. 2005; Walldius et al. 
2001) have emerged as probably potent markers of cardiovascular mortality. Therefore, we designed 
the present case-control study in order to examine the validity of serum lipid proﬁ  le components as 
markers of cardiovascular morbidity, study their signiﬁ  cance as predictors of cardiovascular mortality 
and spot any differences between them.
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Materials and Methods
Patients 
This is a single-centre, hospital-based case-control 
study comprised of ESRD patients on hemodial-
ysis. Follow-up period was 60 months. Out of a 
total of seventy-eight Caucasian patients that were 
eligible for enrolment in the study, seventy-ﬁ  ve 
patients remained eligible until the end of follow-
up (Tables 1 and 2). The other three patients 
received a renal transplant during this period and 
were eventually withdrawn from the study. The 
ﬁ  rst study group was comprised of 25 patients with 
history of prevalent documented CVD during the 
follow-up period (18 males, mean age 63, range 
52–69 years). Of these 25 patients, ﬁ  fteen had a 
history of myocardial infarction, coronary artery 
bypass or angina pectoris evident clinically and on 
ECG, four had suffered an ischemic cerebrovas-
cular event, evident clinically and on CT, and six 
had peripheral vascular disease clinically evident 
and documented by doppler ultrasonography and/
or angiographically. At the time of enrolment into 
the study, no patient had any acute cardiovascular 
accident during the previous three months. The 
second patient group was comprised of 50 HD 
patients (35 males, mean age 62, range 40–77 
years) without a history of prevalent documented 
CVD. Frequency matching for age and sex was 
performed, and a case-control ratio of 1:2 was 
intended. Patients with active infections or acute 
inﬂ  ammation, liver disease, autoimmune diseases 
or malignancies, patients receiving antibiotics, 
corticosteroids or cytotoxic drugs at the time of the 
study as well as patients with fasting serum triglyc-
erides >400 mg/dL (baseline measurement) were 
considered non-eligible for inclusion in the study. 
All patients had been stabilized on renal replace-
ment therapy for ≥6 months (mean duration 65 
months, range 6–210 months) and were clinically 
stable. Patients receiving statin therapy before their 
enrolment in the study were proportionately allo-
cated in the two study groups (Table 2). All patients 
were receiving conventional 4-h HD, three times 
weekly, with bicarbonate dialysate and low-molecular-
weight heparin as standard anticoagulation. Dialysis 
prescription was guided by a goal of achieving a value 
of 0.65 for the urea reduction ratio and a value of 
Kt/V 1.2. The above indices of adequacy of dialysis 
were calculated by the formula [(pre-dialysis urea)–
(post-dialysis urea)/predialysis urea] and by the 
second-generation Daugirdas equation, respectively. 
Thirteen patients (17%) were active smokers. 
Smoking habit was deﬁ  ned as regular tobacco use 
within the previous 5 years. Systolic and diastolic 
arterial BP was calculated as the mean of all consecu-
tive pre-dialysis readings during the month preceding 
the study start point. Mean arterial BP (MAP) was 
calculated as diastolic BP+ ((systolic BP-diastolic 
BP)/3). Diagnosis of hypertension was established 
by standard criteria (1999 World Health Organiza-
Table 1. Demographic and clinical characteristics of the patients.
  HD patients
Males/females (n, %)  53/22,  70/30
Age (mean, range) (years)  62 (40–77)
Primary disease
•  Interstitial nephritis (n,  %)  21,  28
• Glomerulonephritis  (n,  %)  22,  29
•  Diabetic nephropathy (n,  %)  14,  19
•  Vascular diseases (n, %)    5,    7
•  Polycystic kidney disease (n, %)    5,    7
•  Alport’s syndrome (n, %)    5,    7
• Unknown  (n, %)     3,    4
Duration of haemodialysis (mean, range) (months)  65 (6–210)
Kt/V  1.19 ± 0.24
BMI (mean, range) (kg/m
2) 24.5  (19.5–25.6)
Cardiovascular disease (n,  %)  25,  33
•  Coronary heart disease (n,  %)  15,  20
•  Cerebrovascular disease (n, %)    4,    5
•  Peripheral vascular disease (n, %)    6,    8
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tion, 1999). Approval of the study by the institu-
tional review board was obtained and informed 
consent was obtained from each patient.
Methods
Blood samples from HD patients were taken
 from 
a peripheral vein under overnight fasting condi-
tions, in the morning of a midweek routine
 dialysis 
day. Serum samples were separated from clotted 
blood
 by immediate centrifugation (1500 g for 15 
min), aliquoted and
 stored at –40°C until assayed. 
Nephelometry was used for the quantitative deter-
mination of serum high sensitivity C-reacting 
protein (CRP) levels. Automated latex enhanced 
turbidimetric immunoassay was used for the 
quantitative determination of Lp(a) in the serum, 
and immunoturbidimetric assay with the use of 
speciﬁ  c antiserum for apolipoprotein A-I and B 
determination. Reference value ranges for apoA-I, 
apoB, Lp(a) and CRP were 1.10–2.15 g/L, 0.55–
1.40 g/L, <300 mg/L and 0–5.0 mg/L, respec-
tively. All reagents used were purchased from 
Dade Behring (Dade Behring Inc., Deerﬁ  eld, IL, 
USA). Serum albumin, total cholesterol,
 triglyc-
erides and HDL cholesterol were determined by 
routine
 techniques using an automated analyser 
(Olympus AU 640, Medicon Hellas, Gerakas, 
Greece). LDL cholesterol was calculated using 
the Friedewald
 formula (LDL = total cholesterol–
HDL–triglycerides/5).
Statistical analysis
Data are expressed as mean ± SD and with range. 
Differences in categorical data were tested with 
the use of X
2 statistic. Differences in continuous 
variables were assessed with t-test, after testing 
Table 2. Demographic data and clinical characteristics of the patient groups.
  Prevalent CVD  Not prevalent CVD  P value
 ( n = 25)  (n = 50) 
Age (mean, range) (years)  63 (52–69)  62 (40–77)  0.47
HD duration (mean, range) (months)  63 (17–210)  67 (6–210)  0.03
Kt/V  1.20 ± 0.3  1.19 ± 0.6  0.6
BMI (mean, range) (kg/m
2)  24.0 (19.5–30.6)  24.1 (20.0–28.4)  0.13
Pre-dialysis systolic BP (mmHg)   143 ± 18  139 ± 16  0.03
Pre-dialysis diastolic BP (mmHg)  83 ± 8  85 ± 6  0.05
Pre-dialysis MAP (mmHg)  103 ± 11  102.7 ± 9.2  0.072
Diabetes mellitus (n, %)  4,   16  10,   20  0.8
Active smoking (n, %)  5,   20    8,   16  0.08
Dialyzer membrane (n, %)
•  Hemophan  15,   60  29,   58  0.76
•  Polysulfone    8,   32  15,   30  0.4
•  Polyacylonitryle   2,    8    6,   12  0.3
Erythropoetin (iv) treated (n, %)
•  Epoetin alfa  12,   48  23,   46  0.42
•  Epoetin beta    4,   16  10,    20  0.06
•  Darbepoetin alfa    5,   20  13,   26  0.05
Antihypertensive medication used:
• CCBs  (n, %)  18,   72  35,   70  0.26
•  CEIs or ARBs (n, %)    7,   28  12,   24  0.3
•  Β-blockers (n, %)    3,   12   5,   10  0.35
Lipid lowering therapy used:
• Statins  3  6  0.8
• Fibrates  0  0
• Other  0  0
Antiplatelet medication used:
•  Ticlopidine  12,   48  22,   44  0.07
•  Aspirin    3,   12   5,   10  0.2
•  Clopidogrel    6,   24   6,   12  0.03
Abbreviations: CCBs: Ca
++-channel inhibitors; CEIs: converting enzyme inhibitors; ARBs: angiotensin-II receptor blockers.
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for normal distribution with the Kolmogorov-
Smirnov test. Serum CRP levels followed a 
skewed distribution to the left and, therefore, were 
log-transformed before analyzed (logCRP). 
Correlations were tested by regression analysis 
or Pearson correlation analysis, as appropriate. 
Diagnostic accuracy of the parameters was 
evaluated with the determination of diagnostic 
sensitivity and speciﬁ  city, the likelihood ratio 
(LR) and the receiver operating characteristics 
(ROC) curve of each, which enabled us to identify 
the best cut-off value. These cut-off points were 
calculated and used to transform individual 
continuous parameters into binary endpoints. The 
calculations were performed using SPSS v. 11.0.0 
statistical software (SPSS, Inc, Chicago, IL, 
USA). A two-tailed P-value  <0.05 was consid-
ered statistically signiﬁ  cant.
Results
Mean values and distributions
The mean serum apoA-I, apoB and Lp(a) 
concentrations were 1.16 ± 0.15 g/L, 1.22 ± 0.2 
g/L and 350 ± 160 mg/dL in males and, respec-
tively, 1.21 ± 0.2 mg/dL, 1.21 ± 0.23 g/L and 
420 ± 200 in females (P < 0.001 for all three 
variables). The mean apoB/apoA-I ratio was 
1.09 ± 0.27 in men versus 1.06 ± 0.36 in females 
(P < 0.05). Serum apoA-I, apo-B and Lp(a), 
levels were found to follow a normal distribu-
tion, as was the apoB/apoA-I ratio. However, 
CRP levels followed a skewed distribution to the 
left and, therefore, were log-transformed before 
analyzed. Mean serum levels for the two study 
groups are shown on Table 3. 
Association of apoB levels and 
apoB/apoA-I ratio with 
cardiovascular morbidity
On correlation analysis, apolipoproteins and their 
ratio were found to be correlated with cardiovas-
cular morbidity, i.e. apoA-I negatively and apoB 
and apoB/apoA-I ratio positively (r = –0.6, P < 0.05; 
r = 0.659, P < 0.01; and r = 0.614, P < 0.01, respec-
tively). Furthermore, logCRP exhibited as well a 
signiﬁ  cant positive correlation with cardiovascular 
morbidity (r = 0.704, P < 0.001), not this being the 
case for Lp(a) which was not found to exhibit such 
a correlation (r = 0.05, P = NS). None of the classic 
lipid parameters (total cholesterol, HDL, LDL, 
triglycerides) was correlated with CVD prevalence 
(r = –0.15, P = NS; r = –0.04, P = NS; r = 0.07, 
P = NS; and r = –0.29, P = NS, respectively). 
Moreover, apoB levels did not correlate with LDL 
levels (r = 0.06, P = NS). When the diagnostic 
characteristics of the tests for all molecules under 
study were analyzed in comparison, the molecule 
with the highest sensitivity, speciﬁ  city and likelihood 
ratio for cardiovascular morbidity and AUC in RO 
curves was apoB, with the apoB/apoA-I ratio 
following in close, for values above the cut-off point 
of 1.26 g/L and 1.13, respectively, which were found 
to be the values combining both the highest sensitivity 
Table 3. Laboratory examinations of the study groups.
  Not prevalent CVD (n = 50)  Prevalent CVD(n = 25)
ApoA-I (g/L)  1.26 ± 0.2
† 1.04  ±  0.1
†
ApoB (g/L)  1.13 ± 0.18
†  1.39 ± 0.14
†
ApoB/apoA-I  0.92 ± 0.26
†  1.35 ± 0.17
†
Lp(a) (mg/L)  359 ± 275
†  460 ± 260
†
CRP (mg/L)  3.5 ± 1.8
†  7.8 ± 4.0
†
Total cholesterol (mmol/L)   4.89 ± 1.11
†  3.80 ± 0.98
†
LDL-C (mmol/L)  2.90 ± 0.98
†  2.12 ± 0.65
†
HDL-C (mmol/L)  1.01 ± 0.26
†  0.93 ± 0.18
†
Triglycerides (mmol/L)  2.15 ± 1.14
†  1.63 ± 0.73
†
Hemoglobin (g/L)  114 ± 11  115 ± 12
White blood cell count(x10
9/L)  7.2 ± 1.6  7.5 ± 1.7
Platelet count (x10
9/L)  276 ± 77  277 ± 88
Albumin (g/L)  40 ± 3  39 ± 4
† P < 0.05, when patients with prevalent CVD were compared to patients without prevalent CVD.
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and speciﬁ  city scores (Table 4). Serum apoA-I was 
shown to be of inferior strength as marker of cardio-
vascular morbidity, with likelihood ratio of 2.8. 
As apoB levels and apoB/apoA-I ratio emerged 
to be the most intimate markers of cardiovascular 
morbidity in our study, we focused further on the 
factors affecting their association with CVD. On 
logistic regression analysis (Tables 5 and 6), the 
age- and sex-adjusted OR for the presence of 
CVD was 2.3 (95% conﬁ  dence interval [CI], 2.0 
to 2.7) and 2.0 (95% conﬁ  dence interval [CI], 1.6 
to 2.4) when apoB levels above 1.26 g/L and 
apoB/apoA-I ratio values above 1.13 were 
compared with values below these cut-off points, 
respectively. When adjustments for several patho-
physiological clusters of variables were carried 
out, the OR of CVD associated with apoB levels 
above 1.26 g/L did not change appreciably after 
controlling for non-lipid risk factors [ΒΜΙ, 
smoking status, hypertension, DM] (OR, 2.3; 95% 
CI, 1.9 to 2.7), Lp(a) (OR, 2.3; 95% CI, 1.8 to 
2.8) or markers of inﬂ  ammation [CRP, leuko-
cytes] (OR, 2.2; 95% CI, 1.8 to 2.6). Alike, for 
apoB/apoA-I ratio values above 1.13, the OR did 
not change essentially after controlling for various 
confounders: respectively, non-lipid risk factors 
(OR, 2.0; 95% CI, 1.7 to 2.3), Lp(a) (OR, 2.0; 
95% CI, 1.7 to 2.2) or markers of inﬂ  ammation 
(OR, 1.9; 95% CI, 1.5 to 2.3). In all models of 
both variables, the OR remained meaningful and 
statistically signiﬁ  cant.
Discussion
Lipid proﬁ  le constituents, such as high total choles-
terol and LDL-C levels, which represent classic 
cardiovascular risk factors in the general popula-
tion, have been repeatedly found to convey a rather 
inverse prognostic signiﬁ  cance in patients on HD 
(Lowrie and Lew, 1990; Iseki et al. 2002). In the 
prospective study by Liu et al. it became clear that 
this adverse association between total cholesterol 
levels and mortality is due to the cholesterol-
lowering effect of systemic inflammation and 
malnutrition rather than to a speculated protective 
effect of high cholesterol levels (Liu et al. 2004). 
The search for more accurate markers amongst the 
lipid proﬁ  le has brought to the surface serum apoli-
poproteins, as probably better markers of the 
balance between preatherogenic and atherogenic 
lipoproteins and predictors of cardiovascular risk 
(Shoji et al. 2001; Walldius et al. 2004; Chan and 
Watts, 2006). Their measurement has several 
advantages over HDL-C and LDL-C: fasting 
samples are not required, they are a better index 
of the adequacy of statin therapy and their measure-
ment techniques are standardized (Chan and Watts, 
2006). The present study was set up to determine 
and compare the validity of the serum apolipopro-
teins, their ratio and serum Lp(a) as markers of 
cardiovascular morbidity in patients on HD. ApoA-I 
is the major apolipoprotein constituent of the anti-
atherogenic high-density lipoproteins (HDL). 
Levels of apoA-I are strongly associated with those 
of HDL cholesterol. ApoA-I is critically involved 
in removing excess cholesterol from tissues and 
incorporating it into HDL for reverse transport, 
Table 4. Test characteristics of the parameters, for cut-
off points with the optimal sensitivity and speciﬁ  city 
scores.
 ApoA-I  ApoB  ApoB/apoA-I
Cut-off point   1.025 g/L  1.26 g/L  1.13
AUC
† 0.14  0.894  0.878
95% CI  0.132–0.142 0.889–0.898 0.874–0.883
Sensitivity (%)  55  100  100
Speciﬁ  city (%)  15  75  77
LR 2.8  17.1  9.6
†Area under the curve
Table 5. Odds ratio of CVD associated with apoB 
levels above 1.26 g/L, after various adjustments.
Model No.  Variable  Odds ratio  95% CI
1  Age and sex   2.3  2.0–2.7
2  Non-lipid risk factors
† 2.3  1.9–2.7
3 Lp(a)  2.3  1.8–2.8
4 CRP,  leukocytes  2.2  1.8–2.6
All models are adjusted for age and sex.
†ΒΜΙ, smoking status, hypertension, DM.
Table 6. Odds ratio of CVD associated with apoB/apoA-I 
ratio values above 1.13, after various adjustments.
Model No.  Variable  Odds ratio  95% CI
1  Age and sex   2.0 1.6–2.4
2  Non-lipid risk factors
† 2.0  1.7–2.3
3 Lp(a)  2.0  1.7–2.2
4 CRP,  leukocytes  1.9 1.5–2.3
All models are adjusted for age and sex.
† ΒΜΙ, smoking status, hypertension, DM.
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either directly or indirectly via LDL to the liver. 
ApoB stands for apolipoprotein B-100 and is the 
chief protein component constituent of the athero-
genic very-low-density lipoprotein (VLDL), of 
intermediate-density lipoprotein (IDL) and of LDL 
particles, each particle including one apoB mole-
cule. Consequently, plasma apoB levels reﬂ  ect the 
total numbers of atherogenic particles. In humans, 
VLDL particles carry endogenously synthesized 
triglyceride from the liver into plasma, where they 
undergo lipolysis to IDL by the action of lipopro-
tein lipase. IDL is lipolysed by hepatic lipase, 
converting to LDL, or taken up by the liver via the 
LDL receptor. ApoB is also essential for the 
binding of LDL particles to the LDL receptor for 
cellular uptake and degradation of LDL particles 
(Simon et al. 2005). Lp(a) is an atherogenic lipo-
protein and consists of an LDL-cholesterol particle 
covalently bonded to apoA. Lp(a) is strongly and 
negatively associated with apoA isoform size 
(Marcovina et al. 1995) and is elevated in HD 
patients (Kronenberg et al. 1995), suggesting that 
Lp(a) level or small apoA may account for a portion 
of the increased atherosclerotic CVD or mortality 
in ESRD patients. Several large epidemiologic 
studies have found that apolipoproteins, especially 
apoB or the ratio of apoB to apoA-I, are superior 
to classic lipid proﬁ  le constituents (i.e. total, HDL 
and/or LDL cholesterol) in predicting coronary 
heart disease risk/myocardial infarction (Lamarche 
et al. 1996; St-Pierre et al. 2005; Walldius et al. 
2001; Talmud et al. 2002; Meisinger et al. 2005; 
Jiang et al. 2004; Ridker et al. 2005; Shai et al. 
2004; Moss et al. 1999; Yusuf et al. 2004) in the 
general population. A rather clear advantage of 
these two indices has been indicated as well by 
studies regarding treatment beneﬁ  ts and prediction 
of subsequent risk for acute coronary event in the 
general population (Gotto et al. 2000; Simes et al. 
2002; Pedersen et al. 1998; Roeters van Lennep 
et al. 2000). In ESRD patients, there are scarce 
reports for the value of apolipoproteins as markers 
of cardiovascular mortality and morbidity (Kronen-
berg et al. 1995; Hahn et al. 1983; Shoji et al. 1997; 
Lee et al. 2002). In our study, patients with prom-
inent CVD had elevated serum apoB and Lp(a) 
levels and apoB/apoA-I ratio values, as well as 
lower serum levels of apoA-I compared to patients 
without prevalent CVD. The former had also 
signiﬁ  cantly higher concentrations of serum CRP 
and signiﬁ  cantly lower concentrations of serum 
total cholesterol, HDL, LDL, triglycerides and 
albumin compared to the later. These results 
conﬁ  rmed earlier observations that, among dialysis 
patients, cholesterol and LDL levels are inversely 
rather than directly associated with mortality rates 
(Coresh et al. 1998; Lowrie and Lew, 1990; Iseki 
et al. 2002). In our retrospective study, classic lipid 
levels fail to demonstrate any correlation with CVD 
prevalence. On the contrary, apolipoproteins and 
their ratio exhibited a consistent correlation with 
cardiovascular morbidity. Between the parameters 
studied, apoB exhibited the characteristics (ROC 
curve, area under the curve, LRs) most coherent 
with associated cardiovascular morbidity, with the 
apoB/apoA-I ratio following in close. Both param-
eters were found to be strongly associated with 
CVD, independently of other potential confounders 
(traditional non-lipid risk factors, inﬂ  ammation 
markers and Lp(a)). Quite different results, 
however, have been reported in dialysis patients 
in a two-year survival study by Hocher et al. 
(Hocher et al. 2003), who have found apoA-I or 
apoB not to be signiﬁ  cantly associated with cardio-
vascular mortality. However, cardiovascular 
morbidity was not examined in that study and the 
probable confounding effect of other factors might 
have obscured the probable association of apoli-
poproteins with CVD. Our results are in line with 
the ﬁ  ndings of Simon et al. (Simon et al. 2005), 
who compared the validity of plasma apoB, non-
HDL cholesterol and LDL-C in predicting cardio-
vascular risk, and subclinical atherosclerosis. 
These authors reported that apoB was consistently 
a stronger predictor of coronary heart disease risk, 
as well as peripheral and coronary atherosclerosis, 
than either non-HDL cholesterol or LDL-C. More-
over, it is interesting that other investigators 
(Schaefer et al. 1994) concluded that plasma apoB 
values ≥1.25 g/L may be associated with an 
increased risk for CHD in the general population, a 
cut-off value which is explicitly close to the value 
that came up to us (1.26 g/L). Despite the fact that 
our measurements were done in serum, a discrep-
ancy of no more than 3% from plasma values is 
expected (Abbott et al. 1983). In the existing litera-
ture, there is no hard evidence as yet regarding the 
possible effects of inﬂ  ammation on apoB levels or 
the association between apoB and coronary artery 
disease. In our study no confounding effect of 
markers of inﬂ  ammation (leukocytes, CRP) on apoB 
levels was established. One cannot discriminate, 
however, from the data of our study whether there 
is absolute lack of an effect or whether apoB levels 
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remain eventually elevated due to counter-acting 
effects of overproduction of apoB, which is known 
to occur in HD patients (Chan et al. 1989), and a 
probable apoB-lowering effect of systemic inﬂ  am-
mation and malnutrition. This seeming lack or 
counter-balance of the effect of inﬂ  ammation on 
serum apoB levels probably represent the mecha-
nism underlying the superior predicting signiﬁ  -
cance of apoB and apoB/apoA-I ratio for CVD, 
compared to total cholesterol and LDL-C levels, 
which have been found consistently to be affected 
essentially by systemic inﬂ  ammation in ESRD 
patients, and which were found not to be a reliable 
correlate of cardiovascular morbidity in our study. 
Moreover, although in many conditions LDL 
cholesterol and apoB levels increase in parallel 
(e.g. familial hypercholesterolaemia), in ESRD 
patients, due to hypertriglyceridemia, malnutrition 
or metabolic disturbances, LDL-C levels are often 
phenomenically ‘normal,’ as in our study, yet apoB 
levels are rather elevated due to its overproduction 
and this results in the formation of a small, dense 
form of LDL (pattern B phenotype). This pheno-
type is considered to be of particular importance 
in the pathogenesis of atherosclerosis, since these 
LDL bind less avidly to the LDL receptor which 
mediates its endocytosis in the liver or peripheral 
tissues (Liu and Rosner, 2006). This is a probable 
cause that helps apoB retain their credibility as a 
marker of dyslipidemia as much as treatment target 
for statin therapy, since they ‘represent’ these 
atherogenic small, dense LDL. These advantages 
render apoB measurement a valuable adjunct 
measurement to the existing routine lipid proﬁ  le 
in ESRD patients.
There are several restrictions of the present study. 
First, this is a retrospective study and, as such, its 
results must be conﬁ  rmed by large prospective 
studies. Second, the clinical description of non-CVD 
patients is a rather rough one, and our results should 
be conﬁ  rmed by studies with the use of more inva-
sive methods, such as myocardial perfusion scintig-
raphy, electron-beam CT or coronary angiography. 
Moreover, the conclusions that have been reached 
from this study of cardiovascular morbidity cannot 
be extrapolated to pre-clinical or latent cardiovas-
cular pathology. The validity of the studied param-
eters as markers of atherosclerosis or early cardio-
vascular disease should be further addressed by 
larger studies with the use of delicate methods, such 
as the Doppler measurement of carotid intima-media 
thickness or plaque-score.
Conclusions
This study showed that among the constituents of 
the lipid proﬁ  le that were studied, apoB as well as 
apoB/apoA-I ratio appears to be the markers most 
closely related to CVD in ESRD patients. Both 
were found to be essentially independent markers 
of CVD in dialysis patients, not affected by the 
state of chronic inﬂ  ammation of this population. 
As they are more stable and practical molecules to 
measure, apoB measurement and/or apoB/apoA-I 
ratio calculation should be probably introduced 
into the gamut of risk predictors for atherosclerotic 
disease in HD patients, provided that larger 
prospective studies conﬁ  rm the preliminary results 
of the present study. 
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